FDA OKs Pfizer drug for rare, fast-killing type of leukemia
August 18, 2017
TRENTON, N.J. (AP) — The Food and Drug Administration has approved a new medicine for use against a rare, rapidly progressing blood cancer after other treatments have failed.
The agency approved Pfizer Inc.'s Besponsa for patients with a type of advanced acute lymphoblastic leukemia. By then, life expectancy is low.
"These patients have few treatments available and today's approval provides a new, targeted treatment option," Dr. Richard Pazdur, the FDA's director for cancer drugs, said in a statement.
This year an estimated 5,970 Americans will be diagnosed and 1,440 will die from the can...